HC Wainwright Reaffirms Buy Rating for Capricor Therapeutics (NASDAQ:CAPR)

Capricor Therapeutics (NASDAQ:CAPR)‘s stock had its “buy” rating reiterated by research analysts at HC Wainwright in a research note issued to investors on Tuesday,Benzinga reports. They presently have a $77.00 target price on the biotechnology company’s stock.

Separately, Cantor Fitzgerald increased their target price on shares of Capricor Therapeutics from $25.00 to $30.00 and gave the company an “overweight” rating in a research report on Thursday, November 14th. One investment analyst has rated the stock with a sell rating and six have issued a buy rating to the company’s stock. According to data from MarketBeat, Capricor Therapeutics currently has an average rating of “Moderate Buy” and an average price target of $34.50.

Capricor Therapeutics Stock Performance

Shares of NASDAQ:CAPR opened at $12.65 on Tuesday. Capricor Therapeutics has a 52 week low of $3.52 and a 52 week high of $23.40. The firm has a market cap of $575.20 million, a PE ratio of -11.93 and a beta of 4.08. The firm’s fifty day moving average is $14.40 and its 200-day moving average is $13.93.

Institutional Investors Weigh In On Capricor Therapeutics

Large investors have recently added to or reduced their stakes in the business. Vanguard Group Inc. boosted its holdings in shares of Capricor Therapeutics by 44.4% during the 4th quarter. Vanguard Group Inc. now owns 2,276,784 shares of the biotechnology company’s stock worth $31,420,000 after buying an additional 700,243 shares in the last quarter. Farallon Capital Management LLC bought a new position in Capricor Therapeutics during the fourth quarter worth $31,056,000. Geode Capital Management LLC grew its holdings in Capricor Therapeutics by 37.8% in the fourth quarter. Geode Capital Management LLC now owns 879,468 shares of the biotechnology company’s stock worth $12,139,000 after purchasing an additional 241,279 shares during the period. Altium Capital Management LLC grew its holdings in Capricor Therapeutics by 150.5% in the fourth quarter. Altium Capital Management LLC now owns 714,000 shares of the biotechnology company’s stock worth $9,853,000 after purchasing an additional 429,000 shares during the period. Finally, Woodline Partners LP bought a new stake in Capricor Therapeutics in the fourth quarter valued at $8,693,000. Institutional investors and hedge funds own 21.68% of the company’s stock.

Capricor Therapeutics Company Profile

Capricor Therapeutics, Inc (NASDAQ:CAPR) is a clinical-stage biotechnology company focused on the discovery, development and commercialization of first-in-class biological therapeutics for the treatment of rare disorders. Capricor’s lead candidate, CAP-1002, is an allogeneic cell therapy that is currently in clinical development for the treatment of Duchenne muscular dystrophy.